CervoMed announces positive Phase 2b extension results for neflamapimod in DLB

CervoMed Inc.

New capsule batch yielded higher plasma levels; CDR-SB improved vs old capsules (p<0.001) and vs placebo (p=0.003).
CGIC score improved with new capsules vs old (4.02 vs 4.46, p=0.035); within-subject placebo comparison also significant (p=0.035).
Fall incidence lower with new capsules (7.4%) vs old (14.5%) and vs placebo (18.8%, p=0.04); in ptau181 <2.2 subgroup: 4.0% vs 19.7% (p=0.007).
149 patients entered extension; 94 received new capsules; completion rates 87.3% (old) and 91.5% (new); no new safety signals.
Company plans to complete full 32-week extension and discuss Phase 3 plans with regulators later this year.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.